Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SIRPA Protein (AA 31-370) (Fc Tag)

SIRPA Origin: Human Host: HEK-293 Cells Recombinant >95 % as determined by SDS-PAGE. Active
Catalog No. ABIN2181765
  • Target See all SIRPA Proteins
    SIRPA (Signal-Regulatory Protein alpha (SIRPA))
    Protein Type
    Recombinant
    Biological Activity
    Active
    Protein Characteristics
    AA 31-370
    Origin
    • 28
    • 14
    • 5
    • 5
    • 1
    Human
    Source
    • 31
    • 9
    • 7
    • 2
    • 2
    • 1
    • 1
    HEK-293 Cells
    Purification tag / Conjugate
    This SIRPA protein is labelled with Fc Tag.
    Sequence
    AA 31-370
    Characteristics
    This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 63.5 kDa. The protein migrates as 70-105 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
    Purity
    >95 % as determined by SDS-PAGE.
    Sterility
    0.22 μm filtered
    Endotoxin Level
    Less than 1.0 EU per μg by the LAL method.
    Top Product
    Discover our top product SIRPA Protein
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Buffer
    50 mM Tris, 100 mM Glycine, pH 7.5
    Handling Advice
    Please avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
  • Andrejeva, Capoccia, Hiebsch, Donio, Darwech, Puro, Pereira: "Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 206, Issue 4, pp. 712-721, (2021) (PubMed).

    Wang, Ni, Zhou, He, Gao, Wu, Wu, Wu, Qiu, Zhou, Chen, Pan, Huang, Li, Bian, Yang, Miao, Liu: "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." in: Cancer immunology, immunotherapy : CII, (2020) (PubMed).

    Yu, Qiu, Long, Yang, Zhang, Xu, Chang, Du, Hou, Yu, Zeng, Wang, Sun: "A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety." in: Biochimie, Vol. 151, pp. 54-66, (2018) (PubMed).

  • Target
    SIRPA (Signal-Regulatory Protein alpha (SIRPA))
    Alternative Name
    SIRP alpha (SIRPA Products)
    Background
    Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.
    Molecular Weight
    63.9 kDa
    NCBI Accession
    NP_001035111
You are here:
Support